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Abstract: Evidence for an association between cannabis and psychosis has been documented in
literature in many forms including experimental studies, epidemiological data, and case series.
The association has implications for psychotic outcomes ranging from mild to severe and occurring
over minutes to years. Due to the huge variety of exposures and outcome measures reported, creating
a coherent account of all the available information is difficult. A useful way to conceptualize these
wide-ranging results is to consider the association between cannabis and psychosis as it occurs within
the context of widely used DSM-5 diagnoses. In the present review we examine cannabis/psychosis
associations as they pertain to Cannabis Intoxication, Cannabis-Induced Psychotic Disorder, and
Schizophrenia. This allows for an understanding of the cannabis and psychosis association along
something approaching a continuum. Cannabis intoxication becomes Cannabis-Induced Psychotic
Disorder once certain severity and duration criteria are met and Cannabis-Induced Psychotic Disorder
is heavily associated with future schizophrenia diagnoses.
Keywords: cannabis; marijuana; psychosis; hallucinations; delusions; paranoia; schizophrenia;
intoxication; DSM-5

1. Introduction
Cannabis use is common and becoming more so. There were an estimated 192.2 million users
worldwide between the ages of 15–64 in 2016. This number of worldwide users represents a 16%
increase compared to 2006 [1]. Legalization of cannabis for medical use has contributed to this
increase [2]. In the United States, states that have passed medical cannabis laws have seen greater
increases in illicit cannabis use and in cannabis use disorders compared to states that have not passed
medical cannabis laws [3]. As use has increased, population-level perceptions as to the harmfulness
of cannabis have decreased [4]. Tetrahydrocannabinol (THC) is of course usually considered the
active ingredient but cannabidiol (CBD), several other cannabinoids, and terpenoids play a role in the
pharmacology of cannabis [5].
Cannabis use has been associated with psychotic symptoms and disorders including schizophrenia
across many populations and in many different study designs [6–9]. The nature of this association is
complex and can be rife with confounders. This is especially so when looking at long-term psychotic
outcomes related to cannabis use. There has been debate in the literature as to whether cannabis use is
a causative factor for schizophrenia or whether the association between the two rather represents some
shared vulnerability to both [8,10]. Another putative reason for the association has been that cannabis
use represents an attempt by people with emerging psychosis to self-medicate their symptoms though
recently that explanation has been falling out of favor as a primary explanation [7,9].
While this review focuses on cannabis proper we should note before moving on that synthetic
cannabinoid use is a growing clinical concern due to the significant prevalence and potential for severe
health effects beyond what is seen with cannabis [11,12]. A 2013 survey of 50,000 US high school
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students reported 6.4% of students with past-year synthetic cannabinoid use compared to 25.8% of
students with past-year cannabis use [13]. The US Army Substance Abuse Program in 2012 conducted a
study where they randomly collected 10,000 urine samples and tested for synthetic cannabinoids. That
study reported a 2.5% positivity rate [13]. Synthetic cannabinoids are not tested for on routine clinical
urine drug screens and so will often go undetected even in substance abuse treatment settings [14]. Part
of the difficulty here is that there is a large and increasing number of distinct synthetic cannabinoids
with diverse chemical structures being constantly synthesized making it difficult to develop assays for
everyday clinical use. Compare this with cannabis which is the easiest substance of abuse to “catch”
on urine drug screens [14]. This difficulty of detection along with governmental difficulty in efficiently
identifying and legally controlling each new synthetic cannabinoid draws many people to them [13].
Synthetic cannabinoids are, sometimes dramatically so, associated with psychosis [15]. In regular
cannabis use there is the low-affinity partial agonist THC acting on the CB1 receptor leading to many
of the effects of cannabis use. In contrast, synthetic cannabinoids are full agonists with high affinity at
the CB1 receptor [16]. Given this, it is not surprising that any deleterious effects from the former could
be seen with greater severity and frequency with the latter. Indeed, much has been written about the
harmful effects of synthetic cannabinoids including risk of psychosis [11,12,15,17–21].
The term psychosis in clinical settings refers to a plethora of abnormalities. Psychotic symptoms
occur over a spectrum from acute to chronic and from mild to severe. Manifestations of psychosis
are commonly broken down into “positive” and “negative” symptoms. Positive symptoms include
delusions, hallucinations, disorganized thinking/speech/behavior, and disorganized or abnormal
motor behavior. Negative symptoms include diminished emotional expression, avolition, alogia,
anhedonia, and asociality [22] (pp 87–89). Positive symptoms are abnormal by their presence whereas
negative symptoms represent abnormalities via absence of normal behaviors. Most of the reported
associations between cannabis and psychosis, particularly for acute effects of cannabis use, focus on
positive symptoms. However, there is some evidence of acute effects resembling negative symptoms
as well [23,24].
Psychosis is merely a symptom whereas Schizophrenia is a chronic, lifelong illness, characterized
by the presence of severe psychotic symptoms [22,25] (pp. 99–105). In addition to the chronicity
required for a Schizophrenia diagnosis the concept of “first rank” psychotic symptoms has historically
been used to help differentiate schizophrenia from other psychotic conditions [26]. First rank psychotic
symptoms are relatively severe and are somewhat specific for Schizophrenia [27,28]. First rank
psychotic symptoms include auditory hallucinations, delusional perceptions, experiences of thought
interference, and passivity experiences [26,27]. Schizophrenia can lead to a devastating impairment in
quality of life. Schizophrenia was responsible for 13.6 million disability-adjusted life years worldwide
in 2010 [29]. Because schizophrenia confers extremely high morbidity and mortality it is understandable
that so much attention has been paid to asking whether cannabis use increases one’s risk for developing
it [30].
Cannabis is associated with a range of psychotic symptoms of widely variable severity. Cannabis
is also associated with psychotic symptoms of widely variable timeframes. Cannabis-associated
psychosis can be seen on the order of minutes, hours, days, or weeks in addition to the months and
years timeframe seen in a schizophrenia diagnosis [6,31,32].
A holistic understanding of the link between cannabis and psychosis requires us to look at more
than just schizophrenia. For the current review we will describe the association between cannabis and
psychosis as it plays out in the context of three Diagnostic and Statistical Manual of Mental Disorders,
fifth edition (DSM-5) diagnoses: Cannabis Intoxication, Cannabis-Induced Psychotic Disorder (CIPD),
and Schizophrenia [22]. It is useful to use this lens because the DSM-5 criteria are very widely
used and accepted. This gives us firmer footing to describe different “kinds” of cannabis-associated
psychotic experiences than we would have otherwise. Delineating the plethora of cannabis/psychosis
associations in the literature into these categories is merely meant as a useful way to conceptualize
the associations and is not meant to strictly indicate the original works referenced in this review
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themselves were working with DSM-5 criteria. No single diagnostic framework is used consistently in
the cannabis/psychosis literature with DSM-III, DSM-IV, DSM-5, ICD-8, ICD-9, and ICD-10 diagnoses
all being used at different times as well as the use of a variety of clinical psychosis rating scales.
2. Cannabis Intoxication
This is a diagnosis made when there is recent cannabis use, significant behavioral or psychological
changes that developed during or shortly after cannabis use, and physical stigmata indicating the
intoxication such as conjunctival injection or dry mouth [22] (p. 516). With respect to timing cannabis
intoxication occurs within minutes for inhalational use but onset can take hours when cannabis is
ingested. The symptoms typically last 3–4 hours but depending on dose and tolerance can persist up
to 24 hours [33]. This is basically the standard cannabis “high” documented in the DSM-5 as a mental
disorder in situations where it causes neuropsychiatric symptoms that are problematic.
Psychotic symptoms are not necessary for a cannabis intoxication diagnosis but can be part of
the disorder with the caveat that insight must remain intact and the psychotic symptoms must not
be sufficiently severe or persistent enough to warrant clinical attention for their own sake. If the
symptoms are severe or persistent enough to warrant clinical attention for their own sake, then that
would move us to a CIPD diagnosis. CIPD is discussed in the following section.
Most individuals meeting criteria for Cannabis Intoxication will not present for acute medical care,
so looking at psychotic symptoms within this disorder gives us a sense of what psychotic symptoms
can be associated with cannabis use in non-clinical populations. We can also note that the vast majority
of worldwide cannabis users have at some point met criteria for a Cannabis Intoxication diagnosis
(becoming intoxicated is to some degree the goal of any cannabis use) so the psychotic symptoms
experienced therein have potential to effect a huge number of persons worldwide. Having described
what Cannabis Intoxication is per the DMS-V we can look at the evidence associating cannabis and
psychosis as might be seen within the parameters of this disorder.
A 2004 double-blind placebo-controlled experimental study by D’Souza et al that documented
psychotic symptoms in healthy subjects after intravenous THC administration provides us with a
straightforward and useful example [24]. By administering the Positive and Negative Syndrome Scale
(PANSS) at different timepoints before and after intravenous THC administration, the transient or
“intoxication” effects of THC with respect to psychotic symptoms were able to be followed. The PANSS
is commonly used in research to monitor symptoms of psychosis [34]. The PANSS was administered
60 minutes prior to injection, 10 minutes after, 80 minutes after, and 200 minutes after. It was found
that a modest mean increase in positive symptoms occurred and peaked 10 minutes after injection and
returned to baseline by 200 minutes after injection. A transient increase in mean negative symptoms
also was seen after injection and again symptoms returned to baseline by 200 minutes. Due to the
study design using intravenous THC as opposed to inhaled or ingested THC the results seen here show
quicker on/off effects than what would be experienced in the population at large where inhalation or
ingestion are the common administration routes. The transient increases seen in this study in both
positive and negative symptoms measured via PANSS peaked at approximate scores of 10. Putting
these results in context the possible PANSS scores for either positive or negative symptom subscales are
7 to 49 and PANSS averages for schizophrenic persons have been reported at 18.2 for positive symptoms
and 21.01 for negative symptoms [34]. So, we see that while increases in psychotic symptoms were
seen in this study using healthy subjects the magnitude of symptoms was quite small and transient as
mentioned above. Also, it is notable that a dose–response relationship was seen in this study with
more psychotic symptoms occurring with 5 mg THC injection compared to 2.5 mg THC injection. This
finding of an acute transient increase in psychotic symptoms after intravenous THC administration in
healthy subjects was replicated by Morrison et al. in 2009 [35]. In human laboratory studies, concerning
healthy individuals being administered THC at high doses, it has been approximated that 35–50% will
experience psychotic symptoms [16].
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The largest pool of evidence describing acute transient psychotic symptoms associated with
cannabis use can be found in studies documenting general population cannabis users self-reported
psychotic experiences during acute use. This data also gives us some sense of the proportion of
cannabis users that experience psychotic effects acutely when using the drug in naturalistic settings.
A 2003 review by Green et al. examined 12 studies that surveyed users’ subjective effects when
using cannabis [36]. Three of the studies used open-ended questions to elicit subjective effects while
nine studies used closed-ended questioning (checklists or questionnaires). All studies used had a
sample size over 30. The open-ended studies found 2–14% of subjects reported hallucinations while
6–15% of subjects reported paranoia. The closed-ended questioning studies allowed for results to be
combined when the surveys asked similar or identical questions about subjective effects of cannabis.
Of subjects in closed-ended questioning studies, 19.8% reported hallucinations/visions (N = 3082),
while 51.4% reported paranoia (N = 2708). It is interesting to note that close-ended questioning elicited
more psychotic symptoms than open-ended questioning. Cannabis users were seen throughout these
studies to endorse mostly beneficial effects when describing effects spontaneously and to endorse
proportionally more harmful/bothersome effects when made to consider these via checklists and
questionnaires. This is congruent with the cognitive biases typically associated with substance use
disorders. It is interesting to see this even in this non-clinical population [37].
There is also evidence from a study by Sami et al. that former cannabis users were more likely to
report having had psychotic experiences with cannabis than current cannabis users who were more
likely to report pleasurable experiences [38]. Current users who indicated a future intention to quit
were more likely to have had psychotic experiences with cannabis than current users who indicated no
desire to quit. These findings (along with the differences Green et al reported with open vs closed
questions) suggest a potential “in” for insight-driven interventions for helping people quit cannabis
such as motivational interviewing.
As it is clear many users do not report psychotic effects from acute cannabis use it becomes
important to ask what kind of person is at risk for these bothersome acute effects. Mason et al. looked
at acute psychotic symptoms associated with cannabis use and stratified their cannabis users based on
high or low pre-intoxication scores on the Schizotypal Personality Questionnaire (SPQ) [39]. SPQ was
used as a proxy for baseline psychotic symptoms and can be taken to indicate risk or susceptibility to
psychosis [40]. This study found greater acute transient effects on psychotic symptoms in individuals
with higher SPQ scores at baseline. Acute effects were taken as the difference between Psychotomimetic
States Inventory (PSI) scores 10–15 minutes after use and PSI scores 3–5 days later after at least
24 hours of cannabis abstinence. This result provides evidence that certain individuals, especially those
experiencing some mild psychotic symptoms at baseline, are more prone to acute transient psychotic
symptoms associated with cannabis use than others.
Having described some of the evidence for an acute association between cannabis and psychosis, as
could be seen in a Cannabis Intoxication diagnosis, we will move on to describe Cannabis Intoxication’s
more severe and persistent progeny, CIPD.
3. Cannabis-Induced Psychotic Disorder (CIPD)
Substance-Induced psychotic disorders are recognized by the DSM-5 and are placed in the category
of Schizophrenia Spectrum and Other Psychotic Disorders. Substance-Induced psychotic disorders
related to practically all substances of abuse can be described using this diagnosis [22] (pp 110–115).
A diagnosis of Cannabis-Induced Psychotic Disorder is given when one or both of hallucinations
and delusions are present, the hallucinations and/or delusions developed during or soon after cannabis
intoxication, the disturbance does not occur exclusively during the course of a delirium, and the
disturbance causes clinically significant distress or impairment in social, occupational, or other
important areas of functioning. Other criteria for the disorder are that cannabis should be thought to
be capable of producing the disturbance seen and that the disturbance should not be able to be better
explained by an independent psychotic disorder that is not cannabis-induced (such as pre-existing
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schizophrenia). The DSM-5 suggests that if symptoms last longer than one month a diagnosis other
than CIPD should be considered [22] (p. 110).
Substance-induced psychotic disorders generally can occur in the context of recent intoxication or
withdrawal from a substance (for example with alcohol) but in the case of cannabis only psychotic
symptoms occurring in the context of recent intoxication are thought to appropriately lead to a CIPD
diagnosis [22] (p. 114).
Several things differentiate CIPD from Cannabis Intoxication. First and foremost is that in CIPD
the hallucinations and/or delusions are the focus of the clinical presentation and are severe enough
to warrant clinical attention/treatment as opposed to the psychotic symptoms that can be seen in
Cannabis Intoxication which are more mild and self-limited and are not even required to make that
diagnosis. A further distinction is that the hallucinations in CIPD are experienced without insight
whereas in Cannabis Intoxication the hallucinations when present are experienced with insight intact
and the DSM-5 linguistically downgrades these in places from frank hallucinations to “perceptual
disturbances.” In addition to greater intensity/severity of symptoms CIPD can also have a much longer
duration than Cannabis Intoxication. Cannabis Intoxication will necessarily resolve within 24 hours
whereas CIPD can last for days and even weeks after cannabis exposure [6]. However, criteria for
CIPD could also be met in a presentation only lasting on the order of hours if the symptoms are severe.
The concept of a cannabis psychosis apart from simple intoxication has been recognized for
literally hundreds of years—take the following example from 1779 describing a preparation of cannabis
known as “Bangue”.
“Bangue is an intoxicating herb; in the use of which it is hard to say what pleasure can be found, it
being very disagreeable to the taste and violent in its operation which produces a temporary madness,
that in some, when designedly taken for that purpose, ends in running, what they call a muck, furiously
killing every one they meet without distinction till themselves are knocked on the head like mad
dogs [41] (p. 21).”
Another historical example of the recognition of CIPD consistent cannabis/psychosis association
comes from French psychiatrist Dr Jacques-Joseph Moreau in 1845, describing the effects of hashish:
“acute psychotic reactions, generally lasting but a few hours, but occasionally as long as a week . . .
illusions, hallucinations, delusions, depersonalization, confusion, restlessness and excitement [42].”
A 2016 study using emergency department data from Vallersnes et al gives us a registry data
example of a cannabis/psychosis association consistent with CIPD [43]. This study searched a European
database (Euro-DEN) that tracks Emergency Department (ED) visits for acute recreational drug toxicity.
Over a one-year period across 16 centers they found 90 ED presentations where psychosis was a
presenting complaint and acute cannabis use had occurred. In 31 of those presentations cannabis was
the sole substance reported. This study excluded overdoses/self-harm presentations and allowed for
substances documented to have been used acutely to be patient and observer reported. This second
distinction is particularly important when trying to assess association between acute cannabis use and
CIPD-consistent psychosis since lab-testing for cannabis can be positive long after acute ingestion.
Unfortunately, most of the literature with respect to documented cases consistent with CIPD
diagnoses is limited to case reports and case series and many of the oft-cited examples are from
decades ago. In general we can say that these case reports and series describe acute cannabis use,
psychotic symptoms severe enough to bring the individual to medical attention, symptoms occurring
immediately after cannabis use, and return to baseline several hours to weeks after ingestion [44–51].
The one large study by number of subjects (N = 36,000) looked at American soldiers in Germany and
documented some cases of “toxic psychosis” and “schizophrenic reactions” but did not control for
use of other drugs and alcohol [51]. One of these studies had follow-up enough to document that the
individuals who later relapsed with respect to cannabis use uniformly had recurrence of psychotic
symptoms [49].
The return to baseline functioning as documented in these case reports is crucial in order to
maintain the concept of CIPD. The difficulty in confidently diagnosing CIPD has been widely noted, as
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confirming absence of prior prodromal or psychotic symptoms and then also confirming return to
baseline is quite difficult [31,52,53].
The “fuzziness” of the diagnosis and the dissimilar situations where it applies leads to confusion.
CIPD criteria are met both in cases of extreme intoxication where psychotic symptoms overwhelm
the clinical picture but may be very short lived, and also in situations that—apart from knowledge of
recent cannabis exposure—could appear identical to a first break psychosis as is seen in schizophrenia
(i.e. requiring extended hospitalization and antipsychotic medication).
Despite these problems CIPD remains an important diagnostic construct that should not be
ignored. CIPD allows us to conceptualize that there is a middle ground in the cannabis/psychosis
association between simple intoxication and long-term psychosis. In the following section we will
describe evidence linking CIPD to later schizophrenia diagnoses, thus completing a diagnostic chain
from Cannabis Intoxication to CIPD to schizophrenia.
4. Schizophrenia
Schizophrenia is the prototypical psychotic disorder and is characterized by its chronicity and
severity. Historically a schizophrenia diagnosis has required the presence of so-called first rank
symptoms indicating severe psychosis [26,28]. Schizophrenia is quite common with a global prevalence
of approximately 0.7% [54,55].
DSM-5 diagnostic criteria for schizophrenia are quite detailed [22] (p. 99) so let us paraphrase here
by saying schizophrenia is diagnosed when there are multiple psychotic symptoms present coupled with
a decreased level of work and/or social functioning and the total duration of the disturbance is greater
than 6 months. Two or more active-phase psychotic symptoms including delusions, hallucinations,
disorganized speech, grossly disorganized or catatonic behavior, and negative symptoms must be
present at least a month if untreated. One of the active-phase symptoms must be either delusions,
hallucinations, or disorganized speech [22] (p.99). The remainder of the six-month period required to
make the diagnosis can include prodromal or residual/attenuated symptoms only. The DSM-5 does
not make explicit reference to the historical concept of first rank symptoms however these symptoms
are part of a DSM-5 Schizophrenia diagnosis in most cases given that one of delusions, hallucinations,
or disorganized speech is required by the DSM-5 and delusions and hallucinations are first rank
symptoms [25,27,28].
The association between cannabis and schizophrenia has been a heavily researched and debated
topic in the literature and rightly so. Schizophrenia has a huge morbidity/mortality burden and if
cannabis is a cause or a component cause it would be a highly modifiable risk factor for this devastating
disease [29].
Interest in the cannabis/schizophrenia association was sparked by a study using Swedish military
conscription data led by Andreassson [56]. This data represents >97% of the age 18–20 male population
of Sweden from 1969. Data on substance use including cannabis was collected at time of conscription
and schizophrenia outcomes over the next 15 years were collected and matched with the subjects’
initial reports of cannabis use. The study documented an increased risk for schizophrenia in those who
had ever used cannabis prior to their conscription and documented a dose–response relationship with
respect to number of lifetime uses of cannabis and schizophrenia risk. Zammit et al conducted a 27-year
follow-up of the same cohort and re-analyzed the data [57]. The number of subjects analyzed was
50,053. The Zammit et al. study reported an odds ratio for schizophrenia of 2.2 for ever using cannabis
and an odds ratio of 6.7 for those who had used cannabis more than 50 times. The effect remained after
adjusting for some potential confounders including psychiatric diagnoses at conscription, IQ score,
personality variables concerned with interpersonal relationships, place of upbringing, paternal age,
and cigarette smoking. The adjusted odds ratio for ever using cannabis was 1.5 and the adjusted odds
ratio for >50 cannabis uses lifetime use was 3.1. The association between cannabis use and a chronic
psychotic disorder (either schizophrenia or schizophreniform disorder) in longitudinal studies has
been replicated multiple times [58,59].
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A 2016 meta-analysis of 10 studies (66,816 total individuals across the studies) looking at the
association between degree of cannabis use and subsequent psychotic symptoms found an overall OR
of 3.90 for the heavy users compared to never users [60]. The studies used in this meta-analysis had at
least three groups of cannabis use: never; one or more intermediate levels of use; and a “heavy” level
either by duration of cannabis use, frequency of cannabis use, or total number of times cannabis had
been used lifetime. This meta-analysis included outcomes other than just chronic psychotic disorders
but is very useful as evidence that the dose–response relationship is robust.
It has been reported in a case control study that amongst patients with psychotic disorders those
who used cannabis daily, those who used higher potency cannabis, and those who started at a younger
age tended to experience the onset of psychotic symptoms earlier than those psychotic disorder patients
who did not use cannabis in the same high-risk ways [61]. This can be taken as more evidence of a
dose–response relationship.
There is also a well-established association between CIPD and later schizophrenia. A study using
Danish registry data from 1994–2014 examined the proportion of patients given substance-induced
psychotic disorder diagnoses that would go on to later be given schizophrenia or bipolar diagnoses [62].
These were patients that did not have schizophrenia or bipolar disorder diagnoses before the incident
substance-induced psychotic episode. In this registry study it was reported that 41.2% of patients
with cannabis-induced psychotic disorder eventually converted to schizophrenia. A total of 47.4% of
patients with cannabis-induced psychotic disorder eventually converted to either schizophrenia or
bipolar disorder.
It is intuitive that having a substance-induced psychotic episode, whatever the offending substance,
could be a substantial risk factor for future psychiatric morbidity. That said, in the same Danish registry
study, cannabis had the highest rate of conversion from substance-induced psychosis to schizophrenia
or bipolar disorder out of all substances investigated. Compare that 47.4% rate for cannabis to 32.3%
for amphetamines, 20.2% for cocaine, 27.8% for hallucinogens, and 35.0% for mixed/other substances.
Fifty percent of the cannabis-induced psychosis patients that converted to schizophrenia did so within
3.1 years of the incident psychotic episode while the remaining 50% that ended up converting to
schizophrenia did so over many years. This delayed conversion after the incident CIPD episode can be
looked at as evidence for the CIPD episode being its own entity as opposed to a mis-diagnosed first
episode of schizophrenia.
Other registry studies have also found persons with CIPD-consistent presentations to have a
high rate of conversion to schizophrenia. A Swedish registry study for substance-induced psychosis
converting to schizophrenia found cannabis to have the highest conversion rate of all substances at
18% [63]. A Finnish study of 18,478 inpatient case calculated that 46% of CIPD cases converted to
schizophrenia and this was the highest percentage for any substance [64]. A study using Scottish
data found 21.4% of people with cannabis-induced psychotic disorder eventually converted to
schizophrenia [65]. In that study cannabis had a lower conversion rate than cocaine and solvent-induced
psychoses however the N’s for cocaine and solvent-induced disorders were very small (24 and 14
respectively compared to 276 for cannabis). In the Scottish study “multiple substance” or “other”
substance-induced psychoses showed a conversion rate of 21.5%. Compared to the Danish, Swedish,
and Finnish studies the Scottish data found cannabis-induced psychotic disorder conversion to
schizophrenia to be more similar to the rates for other substances.
It is important to note that most of these registry studies are looking at cannabis use in relatively
young people and subsequent schizophrenia or other psychotic outcomes. Age of onset of cannabis use
appears to heavily influence the cannabis/schizophrenia association [9]. One potential explanation for
this is that cannabis use has stronger effects on developing brains and that is what leads to a stronger
association with future psychoses.
Genetic risk is an important part of the cannabis/schizophrenia association as well. We should
expect this as schizophrenia has often been estimated as having approximately 80% heritability [66].
A study from Gage et al used single nucleotide polymorphisms (SNPs) associated with cannabis
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initiation and SNPs associated with schizophrenia to calculate a small causal effect (OR = 1.04) of
cannabis initiation on subsequent schizophrenia [67]. This study also illustrated the complex and
seemingly bidirectional nature of the cannabis/schizophrenia association, calculating a stronger causal
effect of schizophrenia on cannabis initiation (OR = 1.10). Another genetic study using SNPs found a
similar result with OR = 1.1 for cannabis being causally implicated in schizophrenia and OR = 1.16 for
the reverse [68].
A specific example of genetic involvement in the cannabis/schizophrenia association can be seen
in the COMT gene. The COMT gene codes for the enzyme catechol-O-methyltransferase which is
important in the breakdown of dopamine, particularly in the prefrontal cortex [69]. The Val158Met
SNP is a Methionine to Valine substitution that causes an alteration of enzyme activity. Val/Val
homozygotes have the highest enzymatic activity, Val/Met heterozygotes have intermediate activity,
and Met/Met homozygotes have the lowest activity. This results in Val/Val homozygotes depleting
dopamine the fastest and Met/Met homozygotes the slowest. Dysregulation of dopamine has long
been considered a crucial part of the pathophysiology of schizophrenia and a great deal of research
has been done to investigate the link between COMT polymorphisms and schizophrenia, particularly
with respect to negative symptoms and cognition [69,70]. These studies have shown a variety of
interesting results including some studies demonstrating significant interactions between cannabis
use and COMT genotype and development of schizophrenia [17,71–77]. In 2005 Caspi et al reported
data on 803 individuals born in Dunedin, New Zealand (known as the Dunedin cohort) [76]. These
individuals were followed up periodically from ages 3 to 26. This study found that 13% of adolescent
cannabis users with the Val/Val genotype met criteria for schizophreniform disorder at age 26 while
only 1.4% of non-cannabis-using adolescents with the same Val/Val genotype met criteria for the
disorder. Schizophreniform disorder has the same DSM-5 criteria as Schizophrenia, but this diagnosis is
given when the symptoms are only known to have lasted from 1–6 months. The odds ratios calculated
for adolescent cannabis use and subsequent schizophreniform diagnosis for the three genotypes
were 10.9 for Val/Val, 2.5 for Val/Met, and 1.1 for Met/Met. Genotype by itself without the covariant
of cannabis use was not found to be significantly associated with subsequent schizophreniform
diagnosis. The impressive results from this oft-cited study demonstrate very well the concept that
there appears to be an important gene–environment interaction to be considered when assessing the
cannabis/schizophrenia link. However, attempts to replicate this study have been mixed with both
positive and negative results [78–85]. Subsequent positive results have been seen in studies considering
the combined interaction between COMT genotype, cannabis use, and history of childhood abuse and
subsequent schizophrenia [81,85].
Another example of the COMT gene’s role in the cannabis/schizophrenia association is seen in
a study from Pelayo-Terán et al. published in 2009 [77]. This study looked at 169 patients in Spain
with first-episode psychosis and examined the interaction between COMT genotype and cannabis
use and age of onset of psychotic symptoms and duration of untreated psychosis prior to treatment
presentation. This study found that low enzymatic activity Met/Met patients who were not cannabis
users tended to have a later age of onset of psychosis and a longer period of untreated psychosis
compared to Val/Val or Val/Met cannabis non-users. Longer period of untreated psychosis can be
considered a proxy for more mild symptoms or primarily negative symptoms as it is expected that
severe positive symptoms will be what brings patients to acute medical attention. Based on this data
the Met/Met genotype can be considered something of a protective factor against severe/early disease.
The most salient finding of the study was that cannabis users with the Met/Met genotype did not have
the delayed onset or longer period of untreated psychosis seen in Met/Met non-users. This suggests
that cannabis use changes the natural course of psychotic symptoms typically seen with the Met/Met
genotype. This study also found that cannabis users of any COMT genotype experienced an earlier
onset of symptoms compared to non-users.
In addition to discussing the cannabis/psychosis association with respect to the onset of
schizophrenia we can discuss the impact of cannabis use on people who already have schizophrenia.
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D’Souza et al conducted a double-blind placebo-controlled study where intravenous THC was
administered to Schizophrenia patients already in treatment for schizophrenia and maintained on
stable antipsychotic dosages [86]. The study design was the same as the study on healthy subjects
from the same author described above in the Cannabis Intoxication section of this review [24]. Similar
results were found in the study of healthy individuals with transient increases in positive and negative
symptoms seen via PANSS (although as expected the baseline scores were higher in the schizophrenic
population). It is important to point out that these exacerbations in psychotic symptoms with cannabis
administration were seen despite the schizophrenic patients being on dopamine-blocking antipsychotic
drugs. A higher percentage of schizophrenia patients experienced transient symptom exacerbations
compared to the study with healthy persons [6].
Further, schizophrenia patients with a cannabis use history compared to schizophrenic patients
without a cannabis use history have been documented to have longer and more frequent psychiatric
hospital stays which would seem to indicate a higher symptom burden [87].
5. Discussion
The association between cannabis use and psychosis is important for all stakeholders to understand.
Cannabis users, potential future users, existing schizophrenia patients, families of at-risk persons,
researchers, clinicians, and policy-makers all need to be aware of the multi-modal and complex
relationship cannabis use has to a variety of psychotic outcomes in order for harm to be reduced and
appropriate informed consent be achieved. A measured appreciation of the nuances will be necessary
for rational decision-making going forward.
Rational decision-making regarding this issue is particularly salient at the current time as
legalization (especially in the United States) expands, public perception trends towards considering
cannabis benign or medicinal, and the very nature of the substance being used is functionally changing
vis-à-vis increased potency [4,88–90].
The DSM-5 dominates mental health nosology and so considering the various associations between
cannabis and psychosis in terms of the DSM-5 allows for a better understanding of this complex
issue. Associations between cannabis and psychosis span the full range from mild to severe and
hyper-acute to lifelong. Severity and chronicity are usually positively correlated when it comes to
cannabis-associated psychosis but not always. Psychosis can be seen even with the mildest of the
cannabis-related disorders in the DSM-5, Cannabis Intoxication. When psychotic symptoms associated
with cannabis exceed the threshold of attracting medical attention and/or persist beyond 24 hours that
moves us to a CIPD diagnosis. Awareness of CIPD is key to conceptualizing the full continuum of
cannabis and psychosis associations. CIPD can lead to significant distress and impairment on its own
and is heavily associated with future Schizophrenia [62–65]. Diagnosis of CIPD is seemingly simple
but actually quite complex, as to appropriately diagnose a case of CIPD absence of symptoms prior to
cannabis exposure and return to baseline both need to be known.
The temporality and specificity of cannabis intoxication and CIPD (exposure and then immediate
symptoms) allow us, with reasonable confidence, to say cannabis use “causes” these conditions.
The etiology of schizophrenia on the other hand is very complex and no one factor can be said to
cause schizophrenia. Rather, a multitude of potential component causes influence the likelihood
of schizophrenia via their presence or absence. Cannabis use appears to be a component cause of
schizophrenia but is neither necessary nor sufficient.
Looking at Hill’s criteria for assessing causation and comparing them to the evidence for the
cannabis/schizophrenia association we see we have consistency, temporality, biological gradient,
plausibility, coherence, experiment, and analogy. Weaknesses for cannabis/schizophrenia causality
include the strength of the association often being relatively small (especially when correcting for
confounders) and confidence with respect to specificity being very difficult to achieve [91]. For Cannabis
Intoxication and CIPD all of Hill’s criteria can be accounted for.
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In closing we would point out one glaring weakness in the literature regarding biological gradient.
Several studies have documented some form of dose–response but there is little-to-no evidence
available on THC/CBD ratios or gross CBD amounts in the cannabis used by those who do or do not
then go on to have psychotic outcomes. This is important data to collect as there is evidence that CBD
tends to ameliorate psychotic symptoms associated with THC [92].
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